Real-World study to see how long IBD patients stick with guselkumab
NCT ID NCT07541261
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study will follow 100 people in Saudi Arabia with moderate to severe Crohn's disease or ulcerative colitis who are starting guselkumab. Researchers will measure how long patients continue the treatment in real-world clinics, along with early symptom improvements. No new drug is being tested; the goal is to understand how well guselkumab works outside of clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- guselkumab
- What this could lead to
- If successful, this could show how well guselkumab works in everyday practice for inflammatory bowel disease in Saudi Arabia.
- What could go wrong
- This is an observational study, not a controlled trial. It cannot prove cause and effect, and results may not apply to other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Al Salama Hospital
RECRUITINGJeddah, 23611, Saudi Arabia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a Real-World study reveal the staying power of guselkumab?